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Summary The time dependency of the antitumour activity of (-)-(R)-2-aminomethylpyrrolidine(1,1-
cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) was examined in mice inoculated i.p. with
105 mouse L1210 leukaemia cells. The increase in life span was greater in mice treated with 72mgkg'I
DWA2114R on the 6th day following tumour inoculation than in mice treated at earlier times. Such superior
effects against advanced L1210 were also seen with cis-diammine (1,1-cyclobutanedicarboxylato)platinum(II)
(CBDCA) but not seen with the parent compound, cis-diamminedichloroplatinum(II) (CDDP) or other
antitumour agents devoid of platinum. After the injection of DWA2114R on day 6, most of the ascites tumour
cells accumulated in the S and G2/M phases of the cell cycle and the total cell number markedly decreased
from 108 to less than 106. On the other hand, only a temporary G, arrest and a less than 50% reduction of the
cell number were induced after a similar treatment on day 3. Interestingly, the superiority of DWA2114R for
advanced L1210 was lost in athymic nude mice and mice depleted of T cells by anti-thymocyte antisera. In
addition, mice cured of advanced L1210 specifically rejected re-inoculated L1210 cells. These results indicate
that the superior antitumour activity against advanced L1210 is unique to DWA2114R among the agents
tested (except for CBDCA) and is caused by both an increased drug susceptibility of tumour cells and a
drug-induced antitumour effect mediated by T cells of the host mice.
The antitumour activity of cis-diamminedichloroplatinum(II)
(CDDP) was first described more than 20 years ago
(Rosenberg et al., 1969). CDDP is one of the most potent
antitumour drugs for a variety of human cancers in the clinic
(Loehrer & Einhorn, 1984). However, the severe side effects
of CDDP such as nephrotoxicity, nausea and vomiting,
myelotoxicity, and ototoxicity are dose limiting factors for
constraining clinical use (Stark & Howell, 1978; Prestayko et
al., 1979). A great effort has been made world wide to
develop new platinum analogs with improved antitumour
activity and reduced toxicity. In our laboratories, a series of
platinum complexes carrying asymmetrical alicyclic diamines
have been tested (Morikawa et al., 1990). From these com-
pounds, (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutane-
dicaboxylato)platinum(II) monohydrate (DWA2114R) has
been selected as an agent with improved nephrotoxicity and
potent antitumour activity (Matsumoto et al., 1991).
We have revealed that single i.v. injection (day 1) of
DWA2114R showed potent antitumour activity against
L1210 implanted s.c. (Endo et al., 1992). Thereafter, in
preliminary experiments using advanced L1210 leukaemia in
mice, DWA2114R showed an unexpectedly good therapeutic
effect. This result made us very interested in the time
dependency of the antitumour effect of DWA2114R, since
antitumour agents are generally thought to be less active
against tumours in advanced stages of progression. In this
study, the time dependency of the antitumour activity of
DWA2114R and its mechanisms were examined in mice
inoculated with L1210 leukaemia cells. The results show that
DWA2114R is more active against L1210 in advanced stages
than in early stages. The analysis of the antitumour
mechanisms in this model suggested that both the direct
tumoricidal activity of the drug and T cell mediated
immunity of the host mice play important roles in the
superior effect of DWA2114R against advanced L1210.
Materials and methods
Drugs
DWA2114R and CBDCA were synthesised in our
laboratories by the method described previously (Morikawa
et al., 1990) and CDDP was purchased from Aldrich
Chemical Co. 5-fluorouracil and doxorubicin were purchased
from Kyowa Hakkou Co. Ltd. (Tokyo), cyclophosphamide
was from Shionogi Pharmaceutical Inc. (Osaka), etoposide
was from Nihon Kayaku (Tokyo) and vincristine sulfate was
from Sigma Chemical Co. (St Louis), respectively. Rabbit
anti-mouse thymocyte, anti-asialo GMI antisera and normal
rabbit IgG were purchased from Wako Pure Chemical Indus-
tries Ltd. (Tokyo). All agents were dissolved in saline
immediately before injection.
Animals
Murine L1210 leukaemia cells were passaged in male 6-week-
old DBA/2 mice once a week by intraperitoneal (i.p.)
inoculation of 106 cells and used to evaluate the drug effects
in male 7-week-old (BALB/c x DBA/2)F1 (CDFI) mice. Both
strains were supplied by Charles River, Japan. Testing was
also done in male 6-week-old BALB/c nu/nu mice supplied
by Japan Clea Inc. All mice were housed in an air condi-
tioned room with a 12 h light-12 h dark cycle and given
food (CE-2: Japan Clea Inc.) and tap water ad libitum.
In vivo experimentalprocedures
L1210 cells were harvested from ascites fluid of tumour-
bearing DBA/2 mice, and 105 cells suspended in 0.2 ml of
RPMI 1640 medium (GIBCO, Grand Island, NY) were i.p.
inoculated into CDF, mice on day 0. All drugs were i.p.
injected in a single dose on the appropriate day. Rabbit
antisera were i.p. injected 4 h before the injection of
DWA2114R on days 3 or 6. Survival of the mice was
monitored and the median survival days of each group was
determined. The injection doses of platinum complexes were
determined on the basis of the lethal dose of each drug in
mice. Three quarters of the LDIo of each platinum complex
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was determined to be 72 mg kg' for DWA2114R,
106 mg kg-' for CBDCA and 13 mg kg-' for CDDP. Statis-
tical analysis of the antitumour activities of the drugs was
conducted by the generalised Wilcoxon test and a P value
less than 0.05 was defined as a statistically significant result.
To evaluate the cytocidal activity of the drugs in vivo, the
number and distribution of the cell cycle of ascites cells of
tumour-bearing mice treated with drugs or vehicle were
estimated at different times after tumour inoculation. The
viability of cells harvested by peritoneal lavage with RPMI
1640 medium was determined by the trypan blue dye exc-
lusion method.
Cell cycle analysis
Ascites cells for flow cytometrical analysis were prepared by
a procedure described in detail elsewhere (Akamatsu et al.,
1991). Briefly, cells were fixed with 70% ethanol immediately
after the harvest. The fixed cells were treated with RNase to
digest double-strand RNA, then stained with solution of
50 lgml-l propidium iodide. The stained samples were
analysed for DNA content with a FACScan (Becton Dickin-
son, CA).
Results
Time dependency ofthe antitumour activities ofDWA2114R
and other antitumour agents
The effect of the timing of drug-injection on the antitumour
activities of DWA2114R was examined in mice i.p.
inoculated with 105 L1210 cells (Table I). The mice were
injected with a single dose of 48 or 72 mg kg-' DWA2114R
on days 1, 3, 6 or 8 after the inoculation of L1210 cells.
Interestingly, DWA21 14R showed its highest antitumour
activity by injection on day 6 at both doses. The median
survival time ofthe mice injected with 72 mg kg-' DWA21 14R
on day 6 was about 2-times greater than that on day 1 in both
experiments. However, such an increase in survival time was
lost by injection on day 8. Interestingly, a similar enhanced
activity against advanced L1210 was also shown by equitoxic
dose of CBDCA but not shown by CDDP (Table II).
CBDCA as well as DWA21 14R showed the greatest
antitumour activity after the injection on day 6. On the other
hand, the survival time of the mice treated with CDDP was
longest in early injection (day 2) and decreased slightly in
progressive order on days 4, 6, and 8.
The time dependency of antitumour activity was also
examined for other types of antitumour agents which are
devoid of platinum. Four mg kg-' doxorubicin, 60 or
80 mg kg- 5-fluorouracil, 100 mg kg-' cyclophosphamide, 1
or 2 mg kg-' vincristine sulfate or 20 mg kg- etoposide was
i.p. injected into tumour-bearing mice in an early stage (day
2 or 3) or late stage (day 6) of tumour progression (Table
III). These agents were more effective by early injection than
late, although the differences were not statistically significant
in the case of cyclophosphamide or etoposide. The enhance-
ment of antitumour activity by late injection was shown only
in DWA2114R among these agents.
Number ofascites tumour cells after DWA2114R injection
In order to determine the effect of DWA2114R on tumour
cell proliferation, the number of ascites tumour cells was
monitored after inoculation of 105 L1210 cells. As shown in
Figure 1, the number of tumour cells per mouse in the
control group increased by 10-fold (106/mouse) on day 3 and
by 1000-fold (108/mouse) on day 6. Maximally, about 3 x 108
cells were present on day 7 and maintained this level until the
animal's death. In the mice injected with 72 mg kg-'
DWA2114R on day 3, the ascites cell number decreased by
50% on day 6 and maintained this level until day 9. How-
ever, the number then rapidly increased and reached about
108 cells per mouse on day 13. In contrast, the 108 ascites
cells number was drastically decreased by more than 99%
after the same treatment with the drug on day 6, and less
than 106 cells remained on day 15. These results are consist-
ent with the therapeutic effect of DWA21 14R mentioned
above.
Cell cycle analysis
The in vivo effect of DWA21 14R on the cell cycle progression
of ascites cells was analysed by using a flow cytometer
(Figure 2). Most of the cells from mice without drug treat-
ment on day 3 were present in the GI phase of the cell cycle.
In contrast, the non-treated ascites cells on day 6 showed a
typical cell cycle pattern of exponentially proliferating cells
and the ratio of the cells in the S and G2/M phases was much
higher than that on day 3. The injection of DWA2114R on
day 3 slightly decreased the cells in the S phase but increased
the GI peak following 72 h (day 3 to 6). However, the ratio
of cells in the S and G2/M phases was markedly increased
240 h (day 13) after the drug injection, consistent with the
increase in the cell number as shown in Figure 1. In contrast,
the day 6-injection of DWA2114R drastically decreased the
GI peak and most of the cells accumulated in S and G2/M in
the following 72 h (day 7-9). These cells in S and G2/M
then, almost disappeared and the remaining cells almost
Table I Survival time ofCDF, mice injected with DWA2114R at various times afterinoculation of
101 L1210 cells
Treatment Day ofdrug Survival days Long term
(mgkg-') injection Median Range survivaP None P< vsb Day 6
Exp. 1
None 10.0 10-13 0/10
DWA2114R 1 16.0 13-16 0/6 0.001 0.05
(48) 3 17.0 16-19 0/5 0.001 NS
6 18.0 14->40 1/5 0.001
8 10.0 10 0/5 0.01 0.01
DWA2114R 1 14.0 13->40 1/6 0.01 0.05
(72) 3 19.0 17-21 0/5 0.01 NS (0.1)
6 31.0 17->40 2/5 0.01
8 10.0 10->40 1/5 NS NS (0.1)
Exp. 2
None 9.0 9 0/6
DWA2114R 1 16.5 14-19 0/6 0.01 0.01
(72) 3 17.0 16-20 0/6 0.01 0.01
6 34.0 19 ->40 3/6 0.01
8 9.0 9 0/6 NS 0.01
aSurvival of the mice was observed for 40 days after inoculation of L1210 cells. bStatistical
significance ofsurvivaltimeofthedrug-treated groups vsthatofthecontrol(None)orthatoftheday
6-injected group (Day 6) at each dose was evaluated by generalised Wilcoxon test. NS = not
significant.ANTITUMOUR EFFECT OF DWA21IR4 ON ADVANCED L1210 829
Table H Comparison oftime dependency in antitumour activities ofplatinum complexes against
CDF, mice inoculated with 105 L1210 cells
Treatment Day ofdrug Survival days Long term P< vsb
(mgkg-') injection Median Range survival None Day 6
None 10.0 9-12 0/10
DWA2114R 2 16.0 16-17 0/5 0.001 0.01
(72) 4 19.0 17-23 0/5 0.001 0.01
6 28.0 24->30 2/5 0.001
8 9.5 9-10 0/6 0.05 0.01
CBDCA 2 18.0 16-18 0/5 0.01 NS
(106) 4 19.0 16-21 0/5 0.01 NS
6 24.0 17->30 1/5 0.01
8 10.0 10->30 1/5 NS 0.05
CDDP 2 21.0 16->30 1/5 0.01 NS
(13) 4 21.0 19-24 0/5 0.01 NS
6 19.0 18-22 0/6 0.01
8 9.0 9-15 0/6 0.05 0.05
aSurvival of the mice was observed for 30 days after inoculation of L1210 cells. bStatistical
significance ofsurvival timeofthedrug-treated group vsthat ofthecontrol(None) orthatoftheday
6-injected group (Day 6) in each drug was evaluated by generalised Wilcoxon test. NS = not
significant.
Table III Comparison between survival time of CDF, mice injected with the
antitumour drug on day 2 or day 3 and that on day 6 after inoculation of 10' L1210
cells
Treatment Day ofdrug Survival days Long term
(mgkg') injection Median Range survival P<b
Exp. I
Saline 2 9.0 9-12 0/7
6 9.0 9-11 0/7 NS
Doxorubicin 2 18.5 15-23 0/6
(4) 6 10.5 10-12 0/6 0.01
5-fluorouracil 2 14.0 13-15 0/6
(60) 6 12.0 11-12 0/6 0.01
Cyclophosphamide 2 18.5 17->40 1/6
(100) 6 18.5 15-21 0/6 NS
Vincristine sulfate 2 13.0 11-14 0/6
(1) 6 10.0 10 0/6 0.01
Exp. 2
Saline 3 9.0 9-10 0/6
6 9.0 9-11 0/6 NS
5-fluorouracil 3 17.0 15-18 0/6
(80) 6 13.0 12-13 0/6 0.01
Cyclophosphamide 3 20.5 19-29 0/6
(100) 6 19.0 19-20 0/6 NS
Vincristine sulfate 3 14.5 12-18 0/6
(2) 6 12.0 11-13 0/6 0.05
Etoposide 3 14.0 11-16 0/5
(20) 6 12.0 11-12 0/5 NS
DWA2114R 3 20.5 19->40 1/6
(72) 6 40.0 31->40 5/6 0.05
aSurvival of the mice was observed for 40 days after inoculation of L1210 cells.
bGeneralised Wilcoxon test was used for the statistical evaluation. NS = not
significant.
appeared in the GI phase 168 h after drug injection (day 13).
At this time, about 2 x 106 tumour cells were present in the
peritoneal cavity, as described in Figure 1.
The role ofthe host immune system in survival ofdrug-treated
mice
We checked whether T cells of the host mice contributed to
the superior effect of DWA2114R against advanced L1210
since T cells are thought to be important for the elimination
of tumour cells in advanced stages of tumour progression.
Seventy two or 48 mg kg-' DWA21 14R was i.p. injected into
athymic BALB/c nude mice on days 1, 3, 6 or 8 after i.p.
inoculation with 10' L1210 cells. As shown in Table IV, the
median survival time of the control mice was 9 days, which
was almost the same as that of CDF1 mice as described
above (Tables I, II and III). However, no advantage of
injection in advanced stage of tumour progression on the
antitumour activity of DWA2114R was seen in the nude
mice. DWA21 14R showed its highest activity after the injec-
tion on day 1 at both doses and the activity decreased in the
order: days 3, 6 and 8.
A critical role of T cells was also convincingly demon-
strated using anti-thymocyte antisera. CDF, mice inoculated
with L1210 cells were treated with rabbit anti-thymocyte or
anti-asialo GM1 antisera to eliminate T cells (Kataoka et al.,
1985) or NK cells (Habu et al., 1981) 4h before the drug
injection. As shown in Figure 3, pretreatment with anti-
thymocyte antisera reduced the antitumour activity of
DWA2114R injected on day 3 (about 30% reduction: not
significant) or on day 6 (about 50% reduction: P<0.05). On
the other hand, the injection of anti-asialo GMI had no
effect on the activity of DWA2114R.
We then examined whether the mice cured of L1210830 K. AKAMATSU et al.
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Figure 1 Change of the number of ascites L1210 cells after i.p.
injection of 72 mg kg-' DWA21 14R. CDF, mice were i.p.
inoculated with I05 L1210 cells on day 0 and given DWA2114R
on day 3 (A) or day 6 (K). Closed circles represent controls.
Points indicate mean number of three or four mice and bars
indicate s.d.
leukaemia by treatment with DWA2114R could eliminate
reinoculated L1210 cells. Six mice survived for 35 days after
50 CDF, mice inoculated with 105 L1210 cells per mouse
were injected with 72mgkg-' DWA2114R on day 6. Three
of these cured mice were reinoculated with 105 L1210 cells,
the remaining 3 mice with 105 P388 leukaemia cells. All the
mice reinoculated with L1210 cells survived for more than 60
days, whereas none of them inoculated with P388 cells sur-
vived more than 20 days.
Discussion
In this study, the antitumour activity of DWA2114R against
L1210 leukaemia was shown to be significantly higher in late
than in early stage of the disease. The survival time of the
mice injected with 72 mg kg' DWA2114R on day 6 was
about 2-times greater than that on day 1 (Table I). Such time
dependency of the antitumour activity is unique to two
CDDP analogs, DWA2114R and CBDCA since the parent
compound CDDP and other antitumour agents showed
higher antitumour activity in the early rather than in the late
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Figure 2 Effects of i.p. injection of 72mg kg-' DWA2114R on
the cell cycle progression of ascites L1210 cells. CDF, mice were
i.p. inoculated with 105 L1210 cells on day 0 and given
DWA2114R on day 3 or day 6. Cells were harvested from the
peritoneal cavity at the time indicated in the figure and analysed
using flow cytometer.
administration by injection (Tables II and III). These results
suggest that DWA2114R and CBDCA have certain unique
properties in their antitumour mechanisms.
The kinetics of the proliferation and the cell cycle progres-
sion of the ascites cells suggest that the susceptibility of the
L1210 cells to DWA2114R is much higher on day 6 than on
day 3 (Figures 1 and 2). The injection ofDWA2114R on day
6 induced S and G2/M arrest, whereas the same treatment on
day 3 only slightly induced GI arrest. From the results of our
experiments using exponential L1210 cells in culture, we
previously reported that G2 arrest is critical for the cytotox-
icity of DWA2114R, whereas GI arrest was not observed
under such conditions (Akamatsu et al., 1991). This may
explain why most of exponential cells on day 6 are highly
susceptible to the cytotoxicity of DWA2114R. On the other
Table IV Survival time ofBALB/c athymic nude mice injected with DWA21 14R at various times
after inoculation with 105 L1210 cells
Treatment Day ofdrug Survival days Long term P< vSb
(mgkg-') injection Median Range survival None Day 6
None 9.0 9-11 0/6
DWA2114R 1 15.5 13-23 0/6 0.01 0.05
(48) 3 15.0 14-16 0/6 0.01 0.01
6 13.5 12-14 0/6 0.01
8 9.0 9-11 0/6 NS 0.01
DWA2114R 1 19.0 15->40 1/6 0.01 0.01
(72) 3 16.0 15-17 0/6 0.01 0.01
6 14.0 14-15 0/6 0.01
8 9.0 9-10 0/6 NS 0.01
'Survival of the mice was observed for 40 days after inoculation of L1210 cells. 'Statistical
significance ofsurvival timeofthedrug-treated group vsthatofthecontrol (None)or that oftheday
6- injected group (Day 6) at each dose was evaluated by generalised Wilcoxon test. NS = not
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Figure 3 Reduction of the antitumour activity of DWA2114R
by anti-thymocyte antisera. CDF, mice inoculated with 105 L1210
cells were i.p. injected with anti-thymocyte antisera (Thy), anti-
asialo GM1 antisera (AsGM1) or normal rabbit IgG (NRG) 4 h
before the injection of 72 mg kg-' DWA2114R on day 3 (open
column) or day 6 (dotted column). Columns indicate mean sur-
vival days of mice and bars indicate s.e.
hand, the resting cells, which are the majority of cells on day
3, may be arrested in GI in a reversible fashion. A direct
comparison of the effect of DWA21 14R on exponential cells
with that on resting cells will be required to confirm this
hypothesis.
However, the enhanced drug susceptibility in exponential
cells is not unique to DWA2114R. Almost all antitumour
agents are more active against exponentially growing cells as
compared to resting ones (Bruce et al., 1966; Van Putten et
al., 1972; Bhuyan et al., 1977). In addition, the flow cytomet-
rical pattern of the drug-treated cells after the day 6-injection
of DWA21 14R showed no increase in cell debris. This means
a large proportion of the cells arrested in S and G2/M must
be rapidly eliminated from the peritoneal cavity of host mice.
This suggests that the superiority of DWA21 14R against
advanced L1210 should be a result of certain unique actions
mediated by the immune systems of host mice. In this regard,
the contribution of T cells to the antitumour activity of
DWA2114R was reasoned as follows. The superiority of
DWA2114R against advanced L1210 was not observed in
athymic nude mice (Table IV) and was lost in mice depleted
of T cells by injection of anti-thymocyte antisera (Figure 3).
The reduction in the antitumour activity of DWA2114R by
the injection of such antisera was larger in the mice treated
on day 6 than in those treated on day 3. Moreover, mice
cured of advanced L1210 rejected reinoculated L1210 cells.
These results suggest that T cells are essential for the superior
effect of DWA2114R against advanced tumour and cont-
ribute to the establishment of tumour specific immunity.
Although the experimental systems were different, the
immuno-potentiating activity against tumour cells has also
been seen with other antitumour agents (Kleinerman & Zwel-
ling, 1982; Mokyr & Dray, 1987). It has also been reported
that antitumour immunity is induced in mice treated with
CDDP (Kociba et al., 1970; Sarna & Sodhi, 1978). In an in
vitro system, CDDP has been reported to activate spon-
taneous cell-mediated cytotoxicity (Kleinerman et al., 1980;
Mally et al., 1980) but not to activate T cell mediated
cytotoxicity (Mally et al., 1979). These reports indicate that
CDDP may have some ability to augment host antitumour
immunity. However, the specificity of these rejection res-
ponses to tumour and the uniqueness of CDDP to induce
these rejections were not examined. It is fascinating to con-
sider the possibility that DWA2114R has unique ability to
take advantage of T cell-mediated antitumour immunity. In
this regard, it is suggestive that CBDCA which has the same
slow-reacting leaving groups as DWA2114R showed a similar
time dependency in its antitumour activity. Such similarity
between DWA2114R and CBDCA raises the possibility that
slow-reacting leaving groups might cause the differences
observed between CDDP and these two compounds. More
precise analysis of the role of the immune systems in the host
mice using various CDDP analogs would elucidate the
critical difference of these compounds.
In conclusion, at least two mechanisms are involved in the
superior effect of DWA2114R against advanced L1210
leukaemia. First, an increased drug-sensitivity of the tumour
cells. Second, T cell-mediated antitumour immunity in the
host mice. As discussed above, the latter is thought to be
critical for the unique effect of DWA2114R in this model.
This experimental system should be useful to elucidate the
role of immunological function in the therapeutic effect of
the antitumour platinum complexes.
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